Key Takeaways
- • Healthcare private equity reached a record $191 billion in global deal value during 2025, surpassing the previous peak of 2021, driven primarily by a sharp increase in mega-deals exceeding $1 billion in size.
- • Deal volume remained robust at 445 buyouts announced in 2025, representing the second-highest transaction count on record, indicating sustained investor appetite across all deal tiers despite regional headwinds.
- • Exit value surged to $156 billion in 2025, the second-highest ever recorded, as sponsor-to-sponsor transactions rebounded sharply from post-pandemic lows, signaling renewed confidence in exit activity and portfolio monetization.
- • Biopharma and healthcare provider segments drove activity, with healthcare IT emerging as a key growth vector attracting substantial capital deployment and transaction volume across the sector.
- • A second-quarter tariff-related slowdown in North America and Asia-Pacific was offset by strong deal momentum in other periods, demonstrating resilience in the healthcare PE market despite macroeconomic pressures and regulatory uncertainties.
Summary
Global healthcare private equity achieved unprecedented deal-making activity in 2025, with total disclosed deal value reaching an estimated $191 billion, according to Bain & Company's Global Healthcare Private Equity Report 2026. This result surpassed the previous record established in 2021, marking a significant inflection point in the sector's investment landscape. The surge was primarily powered by a pronounced increase in large transactions exceeding $1 billion, which became a dominant feature of deal activity across the year despite transient headwinds from second-quarter tariff-related disruptions that temporarily slowed dealmaking in North America and Asia-Pacific regions.
Transaction volume remained exceptionally strong, with investors announcing 445 buyouts throughout 2025—the second-most on record. This robust deal count across all size tiers underscores sustained institutional capital deployment and portfolio construction activity within the healthcare sector. Notably, exit value rebounded to $156 billion, the second-highest level ever recorded, a dramatic recovery from the $54 billion achieved in 2024. This rebound was particularly driven by a sharp increase in sponsor-to-sponsor transactions, reflecting renewed confidence among financial sponsors in executing liquidity events and redeploying capital into new platform acquisitions and add-on investments.
Segment leadership in 2025 was anchored by biopharma and healthcare provider segments, with healthcare IT emerging as a distinct growth catalyst attracting focused investor attention and capital deployment. The medtech segment also demonstrated significant growth, contributing to the diversified nature of PE investment activity across healthcare subsectors. According to Kara Murphy, partner at Bain & Company and co-leader of its Healthcare Private Equity team, "Healthcare private equity delivered a record performance last year as large deals spiked and deal count rose across all tiers, with the biopharma and provider segments leading the way, driven by healthcare IT activity."
The rebound in exit value and sponsor-to-sponsor transactions signals a structural normalization in portfolio monetization timelines and represents a departure from the extended hold periods that characterized the post-pandemic correction. With mature portfolios building across sponsor backlogs and exit pipelines expanding, market participants are positioning for continued elevated activity in 2026, suggesting that 2025's record-setting performance may establish the baseline for ongoing robust healthcare PE dealmaking.
Transaction volume remained exceptionally strong, with investors announcing 445 buyouts throughout 2025—the second-most on record. This robust deal count across all size tiers underscores sustained institutional capital deployment and portfolio construction activity within the healthcare sector. Notably, exit value rebounded to $156 billion, the second-highest level ever recorded, a dramatic recovery from the $54 billion achieved in 2024. This rebound was particularly driven by a sharp increase in sponsor-to-sponsor transactions, reflecting renewed confidence among financial sponsors in executing liquidity events and redeploying capital into new platform acquisitions and add-on investments.
Segment leadership in 2025 was anchored by biopharma and healthcare provider segments, with healthcare IT emerging as a distinct growth catalyst attracting focused investor attention and capital deployment. The medtech segment also demonstrated significant growth, contributing to the diversified nature of PE investment activity across healthcare subsectors. According to Kara Murphy, partner at Bain & Company and co-leader of its Healthcare Private Equity team, "Healthcare private equity delivered a record performance last year as large deals spiked and deal count rose across all tiers, with the biopharma and provider segments leading the way, driven by healthcare IT activity."
The rebound in exit value and sponsor-to-sponsor transactions signals a structural normalization in portfolio monetization timelines and represents a departure from the extended hold periods that characterized the post-pandemic correction. With mature portfolios building across sponsor backlogs and exit pipelines expanding, market participants are positioning for continued elevated activity in 2026, suggesting that 2025's record-setting performance may establish the baseline for ongoing robust healthcare PE dealmaking.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.